Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment.
Tsaur I, Heidegger I, van den Bergh RCN, Bektic J, Borgmann H, Foti S, Hunting JCB, Kretschmer A, Ploussard G, Tilki D, Gandaglia G, Dotzauer R; EAU-YAU Prostate Cancer Working Party. Tsaur I, et al. Among authors: kretschmer a. Eur Urol Focus. 2021 Nov;7(6):1308-1315. doi: 10.1016/j.euf.2020.06.018. Epub 2020 Jul 9. Eur Urol Focus. 2021. PMID: 32653263
[Imaging diagnostics of advanced prostate cancer].
Kretschmer A, Seitz M, Graser A, Stief CG, Tilki D. Kretschmer A, et al. Urologe A. 2013 Apr;52(4):497-503. doi: 10.1007/s00120-012-3095-z. Urologe A. 2013. PMID: 23483268 German.
Male Incontinence: The Etiology or Basis of Treatment.
Hester AG, Kretschmer A, Badlani G. Hester AG, et al. Among authors: kretschmer a. Eur Urol Focus. 2017 Oct;3(4-5):377-384. doi: 10.1016/j.euf.2017.12.002. Epub 2017 Dec 15. Eur Urol Focus. 2017. PMID: 29249687 Review.
Local treatment for metastatic prostate cancer: A systematic review.
Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP. Tilki D, et al. Among authors: kretschmer a. Int J Urol. 2018 May;25(5):390-403. doi: 10.1111/iju.13535. Epub 2018 Mar 23. Int J Urol. 2018. PMID: 29572963
How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
Gandaglia G, van den Bergh RCN, Tilki D, Fossati N, Ost P, Surcel CI, Sooriakumaran P, Tsaur I, Valerio M, Kretschmer A, Zaffuto E, Salomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP). Gandaglia G, et al. Among authors: kretschmer a. BJU Int. 2018 Nov;122(5):823-830. doi: 10.1111/bju.14391. Epub 2018 Jun 3. BJU Int. 2018. PMID: 29772103
277 results